Rare EWSR1::PBX1 Fusion‐Positive Infant B‐ALL With Coexisting KRAS Mutation: Sustained Molecular Remission Achieved With Standard Chemotherapy

Documenti analoghi

• A Rare Case of Infant B‐ALL With SIN3A::NUTM1 Fusion: Durable Molecular Remission Achieved With Standard Acute Lymphoblastic Leukemia Chemotherapy
  di: Dong Peng, et al.
  Pubblicazione: (2026)
• Pediatric B‐Cell Acute Lymphoblastic Leukemia With FUS::FLI1 Fusion in an Infant With Measurable Residual Disease: Sustained Molecular Remission Achieved With Blinatumomab
  di: Qiang Yao, et al.
  Pubblicazione: (2025)
• Sustained Remission in a Pediatric B‐Cell Acute Lymphoblastic Leukemia With Rare PAX5::KIAA1549L Fusion and Complex Karyotype Following Blinatumomab Consolidation
  di: Xiaoyong Chen, et al.
  Pubblicazione: (2025)
• Overcoming Chemotherapy Resistance in EBF1–PDGFRB‐Positive B‐ALL: A Novel Therapeutic Approach Using Dasatinib and Blinatumomab
  di: Jinyu Fu, et al.
  Pubblicazione: (2025)
• Concurrent Somatic Mutations of the SETBP1 and KRAS Genes in Pediatric AML: A Case Report
  di: Ryo Okuse, et al.
  Pubblicazione: (2026)